Researchers at Stanford University have developed “decoy receptor” molecules that inhibit the growth of both multiple myeloma (MM) and diffuse large B cell lymphoma (DLBCL) in mice. The molecules, described in a study to be published July 26 in the Journal of Experimental Medicine (JEM), were also found to be nontoxic in monkeys, suggesting they could be used to treat humans with either of these deadly diseases, which are two of the most common blood cancers around the world.
The discovery of 14 inherited genetic changes which significantly increase the risk of a person developing a symptomless blood disorder associated with the onset of some types of cancer and heart disease is published today in Nature Genetics. The finding, made in one of the largest studies of its kind through genetic data analysis on 421,738 people, could pave the way for potential new approaches for the prevention and early detection of cancers including leukaemia.
Most patients in the study mounted immune responses after a booster dose, and no patient with antibody responses died from COVID-19.
The origins of our blood may not be quite what we thought. Using cellular “barcoding” in mice, a groundbreaking study finds that blood cells originate not from one type of mother cell, but two, with potential implications for blood cancers, bone marrow transplant, and immunology. Fernando Camargo, PhD, of the Stem Cell Program at Boston Children’s Hospital led the study, published in Nature on June 15.
Mount Sinai researchers have for the first time identified genes that predict a good response to a vital new therapy for a blood cancer that can have serious side effects for some patients.
A new study by researchers at Washington University School of Medicine in St. Louis shows that treatment with an immunity boosting protein called interleukin 7 (IL-7) after an infusion of genetically modified T cells causes the cancer-fighting CAR-T cells to grow in number and become more effective at killing tumor cells.
People with blood cancers are at a higher risk than healthy individuals for severe and life-threatening COVID-19 illness; furthermore, research suggests that they do not always achieve optimal protection from vaccination.
Ulrich G. Steidl, M.D., Ph.D., co-director of the Blood Cancer Institute and associate director of basic science at the Albert Einstein Cancer Center (AECC), has received a prestigious Outstanding Investigator Award from the National Cancer Institute (NCI).
Mutations in blood cells likely caused by smoking and aging-related changes may lead to a rare type of blood cancer that affects immune cells, shows a study published today in eLife.
Every year more than 1.3 million Americans will be living with, or be in remission from, a blood cancer. John Conti, M.D. discusses common symptoms and treatment.
A new study at Tel Aviv University found that eosinophils – a type of white blood cells – are recruited to the battle against cancer metastases in the lungs.
Kevin David, MD the director of the lymphoma program and a hematologist/oncologist at Rutgers Cancer Institute of New Jersey shares information about leukemias and lymphomas for blood cancer awareness month.
When most people think about cancer, they tend to think of lumps and bumps, something visible they can see and touch. But with blood cancers, there are no immediate visible signs, just the effects of the cancer in the blood system. John Conti, M.D., explains more.
Lymphoma is a rare form of cancer that affects bone marrow, lymph nodes, the thymus gland and spleen, collectively known as the lymphatic system. To understand more about lymphoma, we spoke with the co-medical director of the Cancer Program at Mountainside Medical Center, Lori Leslie, M.D.
Patients with a type of blood cancer called multiple myeloma had a widely variable response to COVID-19 vaccines—in some cases, no detectable response—pointing to the need for antibody testing and precautions for these patients after vaccination, according to a study published in Cancer Cell in June.
Antibodies aren’t the only immune cells needed to fight off COVID-19 — T cells are equally important and can step up to do the job when antibodies are depleted, suggests a new Penn Medicine study of blood cancer patients with COVID-19 published in Nature Medicine.
Two new studies published in Blood suggest that the mRNA COVID-19 vaccine may have reduced efficacy in individuals with chronic lymphocytic leukemia (CLL) and multiple myeloma, two types of blood cancer.
The risk of childhood leukemia among kids with Down syndrome is higher than predicted, according to a new study led by UC Davis and UC San Francisco researchers. Early diagnosis remains critical.
Surprising role for so-called “jumping” genes that are a source of genetic mutations responsible for a number of human diseases.
A new study from Washington University School of Medicine in St. Louis shows that whole genome sequencing is at least as accurate and often better than conventional genetic tests that help determine the treatment for a patient’s blood cancer. Genome sequencing technology continuously is decreasing in cost and recently reached a level similar to that of conventional testing.
SEATTLE — Feb. 5, 2021 — Today the U.S. Food and Drug Administration approved the chimeric antigen receptor immunotherapy, Breyanzi (lisocabtagene maraleucel or liso-cel), for the treatment of adults with relapsed or refractory (R/R) large B-cell lymphoma after at least two prior therapies.The approval was granted to Bristol Myers Squibb, and development of the therapy was supported by physician-scientists at Fred Hutchinson Cancer Research Center.
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center published promising findings today in the New England Journal of Medicine on preventing a common complication to lifesaving blood stem cell transplantation in leukemia.
Many patients with diffuse large B-cell lymphoma (DLBCL) can be cured by a transplant using their own blood-forming stem cells, but as many as half eventually relapse. New research led by Dana-Farber Cancer Institute scientists suggests that patients whose blood or stem cell samples harbor tumor DNA are likely to relapse.
The novel oral drug venetoclax can be safely added to standard therapies for some high-risk myeloid blood cancers and in early studies the combination shows promise of improved outcomes, say scientists from Dana-Farber Cancer Institute.
Clonal hematopoiesis (CH) is a recently identified condition in which mutations associated with blood cancers are detected in the blood of some healthy, usually older, individuals who don’t have cancer. People with CH, while asymptomatic, have an elevated risk of developing blood cancers and other negative health outcomes, including heart attacks and strokes.
Researchers from The University of Kansas Cancer Center are involved in the presentation of nearly 50 research studies at the 62nd American Society of Hematology (ASH) Annual Meeting.
A new clinical trial offers the most compelling evidence to date that a donor stem cell transplant can improve survival rates for older patients with higher-risk myelodysplastic syndrome (MDS), Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting.
Dana-Farber Cancer Institute researchers will present more than 40 research studies at the virtual 62nd American Society of Hematology (ASH) Annual Meeting on December 5-8, including two studies that were selected for inclusion in the official press program.
The National Comprehensive Cancer Network announces publication of new NCCN Guidelines for Pediatric Hodgkin Lymphoma, one of the most curable forms of pediatric cancer. They synthesize the latest evidence and expert-consensus to make sure every child receives appropriate, but not excessive, treatment.
NCCN publishes a new patient and caregiver resource focused on a childhood cancer type. Free NCCN Guidelines for Patients: Pediatric Acute Lymphoblastic Leukemia (ALL) shares the latest expert advice for treating infants, children, and adolescents with the most common pediatric malignancy.
Patients who develop cytomegalovirus infections after allogeneic stem cell transplantation may be able to develop an immunity against the virus, strengthen their immune system and reduce reliance on strong antiviral medications, a team from Roswell Park reports in the journal Biology of Blood and Marrow Transplantation.
Researchers at Washington University School of Medicine in St. Louis have combined two immunotherapy strategies into a single therapy and found, in studies in human cells and in mice, that the two together are more effective than either alone in treating certain blood cancers, such as leukemia.
Researchers from Rutgers Cancer Institute of New Jersey along with collaborators from Princeton University identify a new drug that has therapeutic effect against the aggressive hematological disease T-cell acute lymphoblastic leukemia.
David Roodman is leading research to investigate a molecule that could repair bone, decrease tumors and improve outcomes for multiple myeloma patients on specific targeted therapies.
Researchers at the Icahn School of Medicine at Mount Sinai have discovered a way to move precision immunotherapy forward by using genomics to inform immunotherapy for multiple myeloma, a blood cancer, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research, in December.
Recent study found that an effective blood cancer treatment was associated with weight gain, obesity, and increased systolic blood pressure